Mammalian genomes encode seven catalytic proteasome subunits, namely, β1c, β2c, β5c (assembled into constitutive 20S proteasome core particles), β1i, β2i, β5i (incorporated into immunoproteasomes), and the thymoproteasome-specific subunit β5t. Extensive research in the past decades has yielded numerous potent proteasome inhibitors including compounds currently used in the clinic to treat multiple myeloma and mantle cell lymphoma. Proteasome inhibitors that selectively target combinations of β1c/β1i, β2c/β2i, or β5c/β5i are available, yet ligands truly selective for a single proteasome activity are scarce. In this work we report the development of cell-permeable β1i and β5i selective inhibitors that outperform existing leads in terms of selectivity and/or potency. These compounds are the result of a rational design strategy using known inhibitors as starting points and introducing structural features according to the X-ray structures of the murine constitutive and immunoproteasome 20S core particles.
Highlights d Direct comparison of proteasome inhibitors by activity-based probes and Ub -G76V-GFP d Short-term b5 inhibition alone is not cytotoxic for MM cells d b5/b2 co-inhibition is the most effective in PI-sensitive and PI-resistant MM d From the available PI, only high-dose carfilzomib provides b5/b2 co-inhibition
Many reagents have emerged to study
the function of specific enzymes
in vitro.
On the
other hand, target specific reagents are
scarce or need improvement, allowing investigations of the function
of individual enzymes in their native cellular context. Here we report
the development of a target-selective fluorescent small-molecule activity-based
DUB probe that is active in live cells and an
in vivo
animal model. The probe labels active ubiquitin carboxy-terminal
hydrolase L1 (UCHL1), also known as neuron-specific protein PGP9.5
(PGP9.5) and Parkinson disease 5 (PARK5), a DUB active in neurons
that constitutes 1 to 2% of the total brain protein. UCHL1 variants
have been linked with neurodegenerative disorders Parkinson’s
and Alzheimer’s diseases. In addition, high levels of UCHL1
also correlate often with cancer and especially metastasis. The function
of UCHL1 activity or its role in cancer and neurodegenerative disease
is poorly understood and few UCHL1-specific activity tools exist.
We show that the reagents reported here are specific to UCHL1 over
all other DUBs detectable by competitive activity-based protein profiling
and by mass spectrometry. Our cell-penetrable probe, which contains
a cyanimide reactive moiety, binds to the active-site cysteine residue
of UCHL1 in an activity-dependent manner. Its use is demonstrated
by the fluorescent labeling of active UCHL1 both
in vitro
and in live cells. We furthermore show that this probe can selectively
and spatiotemporally report UCHL1 activity during the development
of zebrafish embryos. Our results indicate that our probe has potential
applications as a diagnostic tool for diseases with perturbed UCHL1
activity.
Bioorthogonal chemistry can be used for the selective modification of biomolecules without interfering with any other functionality that might be present. Recent developments in the field include orthogonal bioorthogonal reactions to modify multiple biomolecules simultaneously. During our research, we observed that the reaction rates for the bioorthogonal inverse-electron-demand Diels-Alder (iEDDA) reactions between nonstrained vinylboronic acids (VBAs) and dipyridyl-s-tetrazines were exceptionally higher than those between VBAs and tetrazines bearing a methyl or phenyl substituent. As VBAs are mild Lewis acids, we hypothesised that coordination of the pyridyl nitrogen atom to the boronic acid promoted tetrazine ligation. Herein, we explore the molecular basis and scope of VBA-tetrazine ligation in more detail and benefit from its unique reactivity in the simultaneous orthogonal tetrazine labelling of two proteins modified with VBA and norbornene, a widely used strained alkene. We further show that the two orthogonal iEDDA reactions can be performed in living cells by labelling the proteasome by using a nonselective probe equipped with a VBA and a subunit-selective VBA bearing a norbornene moiety.
Subunit-selective
proteasome inhibitors are valuable tools to assess
the biological and medicinal relevance of individual proteasome active
sites. Whereas the inhibitors for the β1c, β1i, β5c,
and β5i subunits exploit the differences in the substrate-binding
channels identified by X-ray crystallography, compounds selectively
targeting β2c or β2i could not yet be rationally designed
because of the high structural similarity of these two subunits. Here,
we report the development, chemical synthesis, and biological screening
of a compound library that led to the identification of the β2c-
and β2i-selective compounds LU-002c (4; IC50 β2c: 8 nM, IC50 β2i/β2c: 40-fold)
and LU-002i (5; IC50 β2i: 220 nM, IC50 β2c/β2i: 45-fold), respectively. Co-crystal
structures with β2 humanized yeast proteasomes visualize protein–ligand
interactions crucial for subunit specificity. Altogether, organic
syntheses, activity-based protein profiling, yeast mutagenesis, and
structural biology allowed us to decipher significant differences
of β2 substrate-binding channels and to complete the set of
subunit-selective proteasome inhibitors.
Most mammalian tissues contain a single proteasome species: constitutive proteasomes. Tissues able to express, next to the constitutive proteasome catalytic activities (β1c, β2c, β5c), the three homologous activities, β1i, β2i and β5i, may contain numerous distinct proteasome particles: immunoproteasomes (composed of β1i, β2i and β5i) and mixed proteasomes containing a mix of these activities. This work describes the development of new subunit-selective activity-based probes and their use in an activity-based protein profiling assay that allows the detection of various proteasome particles. Tissue extracts are treated with subunit-specific probes bearing distinct fluorophores and subunit-specific inhibitors. The samples are resolved by native polyacrylamide gel electrophoresis, after which fluorescence-resonance energy transfer (FRET) reports on the nature of proteasomes present.
This work reports the development of highly potent and selective inhibitors of the β5c catalytic activity of human constitutive proteasomes. The work describes the design principles, large hydrophobic P3 residue and small hydrophobic P1 residue, that led to the synthesis of a panel of peptide epoxyketones; their evaluation and the selection of the most promising compounds for further analyses. Structure-activity relationships detail how in a logical order the β1c/i, β2c/i, and β5i activities became resistant to inhibition as compounds were diversified stepwise. The most effective compounds were obtained as a mixture of cis- and trans-biscyclohexyl isomers, and enantioselective synthesis resolved this issue. Studies on yeast proteasome structures complexed with some of the compounds provide a rationale for the potency and specificity. Substitution of the N-terminus in the most potent compound for a more soluble equivalent led to a cell-permeable molecule that selectively and efficiently blocks β5c in cells expressing both constitutive proteasomes and immunoproteasomes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.